Lifitegrast for dry eye disease: OPUS-3 results
In the 12-week OPUS-3 trial, lifitegrast reduced eye-dryness symptoms more than placebo. A difference appeared by day 14, although not every secondary measure changed consistently.
doi: 10.1016/j.ophtha.2016.09.025